Therapy Areas: Oncology
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
17 September 2026 - Myosin Therapeutics Inc, a clinical-stage biotechnology company developing a new class of therapies targeting cancer cell mechanics, announced on Thursday its selection as a 2026&n...
Jubilant Therapeutics reports preliminary clinical data from Phase 1/2 study in myeloproliferative neoplasms at SOHO 2026
16 September 2026 - Jubilant Therapeutics Inc, a US-based clinical-stage biopharmaceutical company advancing precision therapies for hematological malignancies, announced on Tuesday the presentation o...
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
15 September 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that it has agreed to acquire a potential best-in-class trispecific T cell-engager (TCE) from privately ...
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
14 September 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) on Monday announced that it has published phase III results for its HER2-targeted an...
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
14 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) disclosed on Monday that its Phase III SERENA-4 trial of Etcamah (camizestrant) in combination with palboci...
GSK reports positive Jideytro data supporting potential first-line lung cancer use
14 September 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported positive registrational Phase I/II ARROS-1 data for Jideytro (zidesamtinib) in previously untreated ROS1...